Virbac : Management presentation of 2023 performances: focus on building strategy for the medium term – we see the guidance as cautious
>Feedback from analysts’ meeting: positive operating signs - We found management’s tone very encouraging and convincing on:1/ the integration of the two latest acquisitions (Globion and Sassaeah presented as being an excellent fit/read our comments of 10 October 2023 and 7 March 2024) which could easily double in size, according to the CEO (new production capacities, commercial development, productivity gains, etc.) ; 2/ market trends: i/ end of destocking i...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.